Stockreport

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

MaxCyte, Inc.  (MXCT) 
PDF ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform te [Read more]